Study of antibacterial antibodies in adults with cystic fibrosis
Treatments studied
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at how your body’s antibacterial antibodies work in people with cystic fibrosis. It may help researchers understand immune responses in cystic fibrosis and guide better future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and able to sign consent.
- Your basic vital signs are within safe ranges (blood pressure, breathing rate, oxygen level, heart rate, and temperature).
- You have normal blood test levels (white blood cells, platelets, and hemoglobin) based on the study’s cutoff values.
- You do not have significant heart disease or pulmonary hypertension.
- In the last few months, you have not had a major health decline, big weight loss, or a recent serious lung flare.
- You have not donated a lot of blood or had major surgery recently, and you are at least 50 kg if blood sampling is needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study follows children newly diagnosed with cystic fibrosis to understand how their lung disease develops. It may help doctors better predict disease course and choose the right timing for care.
This study looks at how the body makes antibodies (proteins that fight infection) against COVID-19 in people with cystic fibrosis. It helps doctors understand how well your immune system responds to the virus or vaccine.
This study tests a new method to detect bacteria in the lungs of people with cystic fibrosis (CF) by analyzing mucus samples. It aims to improve how we diagnose and treat lung infections.
This study looks at how a child’s early lung function, viral infections, and gut (microbiome) changes affect cystic fibrosis over time. It may help doctors understand what predicts how lung disease develops, which could improve future care.
This study looks at special blood markers in people with cystic fibrosis who have or haven't been treated for a lung infection caused by nontuberculous mycobacteria. The goal is to better understand the body's response, which could lead to better treatments.
This study looks at how lung infections and inflammation affect people with cystic fibrosis during severe flare-ups. It aims to understand which antibiotics work best and why, so your care team can choose the right treatment for you.
Hear when a new Pulmonary Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.